This commentary highlights that diverse cardioprotective signaling pathways converge on the phosphorylation and inhibition of GSK-3β, which delays the mitochondrial permeability transition and protects against ischemia/reperfusion injury.
Numerous signaling pathways have been shown to mediate cardioprotection, but the end effectors that mediate protection are only beginning to be elucidated. Numerous cardioprotective drugs are shown to converge on glycogen synthase kinase-3β (GSK-3β) . The phosphorylation and inhibition of GSK-3β lead to inhibition or delayed activation of the mitochondrial permeability transition, a key regulator of apoptosis.
No takes yet. Share an insight, caveat, or question.
Elizabeth Murphy (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: